Tim de Gavre takes up BGMA Chair role

Two-year term ahead for Sandoz UK head who succeeds Peter Ballard

(29th May, 2018) The British Generic Manufacturers Association (BGMA) has welcomed Tim de Gavre as its new chair - a role he will hold for the next two years.

Tim replaces Peter Ballard, who will serve a further year as vice-chair of the association, which is the representative organisation for generic medicine manufacturers in the UK.

A former chair of the British Biosimilars Association (BBA) - the sister association to the BGMA - Tim is Head of Sandoz UK.  Tim has worked for Sandoz since 2010 holding a series of leadership roles in Biosimilars and Generics.  Prior to joining Sandoz, Tim worked as a consultant at McKinsey & Company and in healthcare venture capital with Frazier Healthcare Ventures.  He also holds an MBA from The Wharton School and a BA from Princeton University.

Tim de Gavre, said: “It is a huge honour to be asked to be the association’s chair for the next two years. Generics and biosimilars save the NHS over £13 billion on an annual basis, which not only releases NHS money for investment in new medicines but also increases accessibility as more patients can be treated for less. 

“During my tenure as Chair of the BGMA, I want to find ways to support the NHS to better utilise generic medicines, while  creating a more reliable and sustainable environment for manufacturers.  The next two years promise to be critical with the introduction of the Falsified Medicines Directive and BREXIT both taking place in early 2019. I look forward to working with government, the NHS and other members of the BGMA to ensure the association’s voice remains strong and that generics and biosimilars are recognised for the value that they bring to the UK.”  

Warwick Smith, Director General of the British Generic Manufacturers Association (BGMA), said: “Tim will bring enormous passion, experience and commitment to the role of association chair at a time when the sector is facing a number of challenges, not least the impact on medicines supply of leaving the European Union. I would also like to offer thanks for the work of Peter Ballard, who steps down as chair following a two-year period where he provided great leadership and counsel to the association.”

ENDS

For further information contact Jeremy Durrant on 02078667883 / 07792918648 or email Jeremy.durrant@britishgenerics.co.uk